At-Home Self-Collection Device for Cervical Cancer Screening Gets FDA Approval
Teal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
Teal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
In this episode of Clinical Lab Chat, Jeff Andrews, MD, FRCSC, of BD, returns to discuss BD and MD Anderson’s HPV self-collection study.
Seegene demonstrated its new HPV diagnostic products and emphasized the importance of HPV screening at the AOGIN conference.
Researchers developed a urine-based test utilizing whole genome sequencing to detect DNA fragments released by head and neck tumors.
Read MoreThe research highlighted factors influencing cervical cancer screening and highlighted the need for interventions to increase screening.
Read MoreThe TTMV-HPV DNA blood test provides a non-invasive method for detecting HPV-driven cancers before there is clinical evidence of disease.
Read MoreThe ASCCP recognized dual-stain biomarkers as an important tech to determine if an HPV infection is transforming into cervical pre-cancer.
Read MoreNaveris Launched an initiative aimed to expand the applications of its circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test.
Read MoreBD partnered with Camtech Health to advance cervical cancer screening by offering women in Singapore the option to self-collect a sample.
Read MoreIn BD’s newest global survey, women reported self-collection would motivate them to have regular cervical cancer screening.
Read MoreResearchers discovered that lymphatic fluid from surgical drains could inform precise treatments for patients with head and neck cancer.
Read MoreRoche announced the U.S. FDA approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.
Read MoreAbbott received FDA approval for its molecular HPV screening solution for its Alinity m family of diagnostic assays.
Read MorePhysically disabled women may encounter barriers to reproductive health care and a lack of timely access to cervical cancer screening.
Read MoreTwo liquid biopsy tests that look for HPV in blood identified patients with a high risk of cervical cancer recurrence after chemoradiation.
Read MoreResearchers developed an electrochemical DNA biosensor which effectively detects HPV-16 and HPV-18, and can diagnose cervical cancer early.
Read MoreScientists at the Montefiore Einstein Cancer Center developed a test for detecting a type of cervical cancer that Pap tests often miss.
Read MoreNew tests offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow.
Read More